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Meso-2,3-dimercaptosuccinic acid
(DMSA, or succimer) is an orally active
cheating agent recently approved by the
U.S. Food and Drug Administration for
the treatment of childhood lead poisoning
(1). Aside from its specified use in children
(2,3), the drug has been reported to be
clinically effective in the treatment ofoccu-
pational plumbism (4-6), mercury vapor
exposure (7) and acute arsenic poisoning
(8). Increases in urinary heavy-metal elimi-
nation have been consistently reported in
these studies, with little effect on essential
mineral excretion (2-5.
Research concerning the pharmacoki-
netics and disposition ofDMSA in humans
includes a phase I [ 4C]DMSA study (9)
and several single-dose HPLC studies
(10-12). Collectively, these studies of nor-
mal male volunteers have led to the concu-
sion that about 20% of an administered
dose is eliminated in the urine; the remain-
der has been presumed to be unabsorbed.
In addition, DMSA appears to be exten-
sively metabolized in that 89% ofthe drug
recovered in urinewas in the form ofmixed
disulfides with the amino acid cysteine
(10); the major metabolite contained two
cysteine residues, while a minor metabolite
contained one.
We conducted a controlled study ofthe
pharmacokinetics of DMSA in children
with elevated blood lead (BPb) concentra-
tions, a subject about which little is known
(13). Because lead poisoning is believed to
inhibit renal uric acid secretion (14) and is
known to impair hepatic cytochrome
P450-mediated drug metabolism (15), we
set out to test the hypothesis that lead poi-
soning might alter the kinetics and disposi-
tion of DMSA. To our surprise, we
observed a pattern of postprandial (after
meals) peaks in urinary DMSAelimination,
which was highlysuggestive ofenterohepat-
ic circulation. We therefore conducted two
additional studies (in adults) to determine
whether the presumed enterohepatic circu-
lation could be blocked by the administra-
tion of cholestyramine and whether gut
microflora are required for DMSA reentry.
During the course of our work, Dart and
co-workers evaluated the pharmacokinetics
ofDMSA in three children and three adults
with lead poisoning and reported that renal
DMSA clearance was decreased in compari-
son to that in healthy adult males (16).
Materials and Methods
The clinical studies were approved by the
Columbia-Presbyterian Medical Center
Institutional Review Board. Informed con-
sent was obtained for each participant.
Drugs and chemicals were obtained
from the following sources: DMSA
(Chemet), in 100 mg capsules, was a gift
from McNeil Consumer Products
Company (Fort Washington, Penn-
sylvania); cholestyramine (Questran Light)
was a gift from Bristol Myers Company
(Evansville, Indiana); dimercaptopropane
sulfonate (DMPS), dithiothrieitol (DTT),
and tetrabutylammonium bromide (TBAB)
were purchased from Sigma (St. Louis,
Missouri); monobromobimane (MBB)
came from Calbiochem-Behring (La Jolla,
California); HPLC-grade acetonitrile came
from Baxter (Muskegon, Michigan);
HPLC-grade methanol and methylene
chloride, sodium acetate trihydrate, sodium
hydroxide, hydrochloric acid, acetic acid,
and ammonium bicarbonate was from
Fisher Scientific (Springfield, New Jersey);
lead nitrate atomic absorption spectrome-
try standard solution was from Alfa
Products (Danvers, Massachusetts); and
Ultrex HNO3 came from J.T. Baker
(Phillipsburg, NewJersey).
Study 1: Pharmacokinetics in
Children
This study aimed to determine 1) whether
environmental lead exposure, as assessed by
blood lead (BPb) levels, influences the
pharmacokinetics of DMSA in children,
and if saturable processes are involved in
the drug's absorption, metabolism, and/or
elimination.
This was a randomized, single-dose,
open-label non-cross-over study. Ten chil-
dren with BPb levels of25-53 pg/dL were
recruited; at the time, elevated BPb was
defined by the Centers for Disease Control
as 25 pg/dL or greater (17). An unpub-
lished study in dogs had suggested that
renal clearance of DMSA might be sat-
urable. Therefore, to determine ifsaturable
processes were involved in absorption,
metabolism, and/or elimination, halfofthe
children received a single oral dose of 350
mg/m2 DMSA (i.e., the recommended
individual dose) and the other halfreceived
2 a dose of700 mg/mi. Children whose ini-
tial BPb was 50 pg/dL or more were imme-
diately given a full 5-day course ofDMSA
(3) at the completion ofthis 56-hr study.
On admission to our Pediatric Clinical
Research Center, each child underwent
baseline laboratory testing and a complete
physical examination. At 0600 hr the next
morning, a single oral dose of 350 or 700
mg/m of DMSA was administered.
Breakfast was withheld until 0800 hr to
prevent possible interference of food with
drug absorption. During the ensuing 56
hr, oral intake of fluids was encouraged
and each urine void was collected and ana-
lyzed for unaltered and altered DMSA as
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described below. In children who were not
toilet trained, urine was collected via a fit-
ted disposable plastic collection bag. To
analyze for unaltered DMSA, portions of
each urine sample were immediately
derivatized with monobromobimane
which prevents the oxidation of the
sulfhydryl groups of DMSA and imparts
fluorescence to it.
Study 2: Influence of
Cholestyramine
This study aimed to determine whether
postprandial increases in plasma DMSA
could be observed. In addition, we sought
to determine whether the suspected entero-
hepatic circulation of DMSA could be
interrupted in vivo by cholestyramine, a
nonabsorbable, nonspecific anionic resin.
We first conducted a pilot study to
determine whether cholestyramine could
bind DMSA in vitro. Standard solutions of
20 mM, 10 mM, 4 mM, and 2 mM
DMSA were prepared from a 40-mM
stock solution using either deionized water
or deionized water containing cholestyra-
mine. The DMSA solutions were elec-
trolytically reduced, derivatized with MBB
(to give final DMSA concentrations of 50
pM, 25 pM, 10 pM, and 5 pM) and then
analyzed by HPLC; DMPS served as an
internal standard in the HPLC analyses
(see "Analysis" below). On average, there
was a 98.5% decrease in the ratios of
DMSA peak area to DMPS peak area
when the DMSA standard solutions were
prepared from the stock solution using
cholestyramine instead ofdeionized water.
Three male and three female normal
adult volunteers were recruited as subjects
for the study: two were Hispanic, two were
African-American, and two were Cau-
casian. Normal physical exams and base-
line laboratory tests (complete blood cell
count and blood chemistries) were
required for enrollment into the study.
This was a single dose, randomized,
cross-over study. Each subject was admitted
twice to the Clinical Research Center. After
an overnight fast, three subjects received 10
mg/kg DMSA orally without cholestyra-
mine, and three received DMSA followed
by cholestyramine orally. Standardized
high-fat meals were given at 5 and 10 hr
after administration of DMSA. When
cholestyramine was given, 8 g were admin-
istered three times at 4, 8, and 12 hr after
DMSA. One week later, the subjects were
crossed over. Eighteen urine samples were
collected over the next 15 hr and analyzed
for unaltered and total DMSA. In addition,
29 blood samples were obtained at specified
intervals over the 15-hr period for measure-
ment oftotal DMSA. Plasma was immedi-
atelyseparated and frozen at -20°C.
Study 3: Influence ofNeomycin
Drug metabolites excreted in bile as polar
conjugates often require hydrolysis by gut
microflora to reform the more absorbable
parent drug molecule (18). The objective
ofthis study was to determine whether gut
microflora are required for the enterohep-
atic circulation ofDMSA.
Although these were not the same sub-
jects as those in study 2, their gender and
ethnic distributions were the same.
Normal physical exams and baseline labo-
ratory tests were required for participation
in this study. Each subject was then admit-
ted twice to the Clinical Research Center
for a single dose, randomized, cross-over
study. After an overnight fast, three sub-
jects received 10 mg/kg of DMSA orally
without neomycin, and three received
neomycin orally the day before the study
(1 g at 0600, 1200, 1800, and 2400 hr)
and DMSA followed by neomycin on the
day ofthe study. The subjects received 1 g
neomycin twice, at 4 and 10 hr after
DMSA. One week later, the subjects were
crossed over. The protocol for blood sam-
pling and the schedule and composition of
meals was the same as for study2.
Analysis
Measurements ofunaltered and altered
DMSA in urine. We used a published
assay (19) based on the HPLC separation
ofa highly fluorescent and stable derivative
of DMSA. The derivative is prepared by
the reaction of the sulfhydryl groups of
DMSA with the methylene bromide moi-
ety ofMBB in aqueous solution at pH 8.3.
We modified the method by adding the
internal standard, DMPS, before the elec-
trolytic reduction step. To assure that our
assay was consistent with that ofMaiorino
et al. (19), portions of approximately 300
urine samples from study 1 were sent to
Maiorino and Aposhian for analysis at the
University ofArizona. There was excellent
agreement between our laboratories.
Briefly, 500 pL of each urine sample
were derivatized immediately after voiding
with MBB and these were analyzed to
determine the concentration of unaltered
DMSA. Separate 20-mL aliquots of each
sample were frozen until analyzed, then
electrolytically reduced and derivatized
with MBB. [Electrolytic reduction of
DMSA was carried out using custom syn-
thesized mercury pool electrolytic cells
connected in series (20)]. HPLC analyses
ofthe latter samples provided total DMSA
concentrations. The concentration of
altered DMSA was obtained as the differ-
ence between the total and free DMSA
concentrations. Quantification was accom-
plished by adding DMSA standards to
"blank" urine samples that were collected
before drug administration and treating
them in the same manner as the post-drug
urine samples (19-21).
We put the remaining volume of each
urine sample in 100-ml sterile polypropy-
lene containers and froze them; aliquots of
these samples were used to determine urine
lead concentrations.
HPLC conditions. A Perkin-Elmer LC-
600 autosampler, LC-250 pump, LS 40 flu-
orescence detector, and model 914 report-
ing integrator were used. The fluorescence
detector was set at an excitation wavelength
of 391 nm and an emission wavelength of
483 nm. Separation was accomplished by
ion-interaction chromatography with a
reverse-phase Spherisorb S5 ODS2 column
(25 x 4.6 mm; 5 pm particle size; Rainin,
Woburn, Massachusetts). Mobile phase A
consisted of 0.02 M TBAB and 0.01 M
acetic acid in methanol; mobile phase B
contained the same concentrations ofTBAB
and acetate in water (pH 4.1). Initial condi-
tions consisted of isocratic elution of 52%
A:48% B for 10 min. Mobile phase A was
then increased to 90% over a 2-min linear
gradient and maintained for 5 min, after
which it was returned to 52%, again over a
2-min linear gradient. Isocratic elution at
52% AA48% B continued for an additional
11 min to re-equilibrate the column. Aflow
rate of 1 mL/min was maintained through-
out the 31-min run.
Urine and BPb analyses. Urine and
BPb concentrations were determined by
graphite furnace atomic absorption spec-
trometry using a modified version of the
method of Fernandez and Hilligoss (22).
Our laboratory is certified for BPb analysis
by the U.S. Occupational Safety and
HealthAdministration. During this study,
there was an intraclass correlation coeffi-
cient of0.97 for the agreement ofour BPb
determinations with the actual values for
OSHA's unknowns.
A Perkin-Elmer Model 3030 Zeeman
atomic absorption spectrophotometer
equipped with an HGA-600 graphite fur-
nace, PR-100 printer, AS-60 autosampler,
and L'vov platform was used for quantitat-
ing urine Pb and BPb. Urine samples were
first diluted with 0.7% Ultrex HNO3 in a
1:1 ratio and then further diluted with
Triton X-100 in a 1:1 ratio, instead of the
1:4 ratio used forwhole blood. The graphite
furnace temperature program was as follows:
130°C for 5 sec, 200°C for 20 sec, ashing at
600°C for45 sec, atomization at 1700°C for
6 sec, and cool down at 20°C for 10 sec.
The first drying stage was ramped for 10 sec
and both the second drying and the ashing
stages were ramped for 15 sec. The detection
limit ofboth the urine and blood assays was
1.0ng/dL (0.05 pM).
Measurement ofDMSA in plasma.
Plasma was analyzed for total DMSA using
a modification of the method described by
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Maiorino et al. (11). We modified the
method by adding the internal standard,
DMPS, before reduction with DTT.
Quantification was accomplished by adding
DMSAstandards to "blank" plasma samples
collected before drug administration and
treating them in the same manner as the
plasma samples collected after DMSA
administration.
The method described for preparing
plasma DMSA standards (11) was also
modified. A 50 mM DMSA in 0.1 M
NaOH (pH 5.3) stock solution was used
to prepare all standards. A 2 mM DMSA
solution was prepared by diluting the stock
solution with distilled deionized water and
intermediate standards of 10, 20, 40, 80,
200, 400, and 800 pM DMSA were pre-
pared by further serial dilution. Buffered
DMPS (6 pM in 0.1 M NH4HCO3) was
used as the internal standard.
For reduction, 50 pL of the DMSA
standard and 150 pL of the blank plasma
were added to a tube containing 50 pL of
100 mM DTT and 1.75 mL of internal
standard buffer (pH 8.2). After purging
with nitrogen for 10 sec and vigorously
mixing for 1 min, the contents were incu-
bated in the dark for 30 min at room tem-
perature. The solution was then ultrafil-
tered in 2 mL Centricon 30 microconcen-
trators bycentrifugation (Sorvall RC-5B) at
6000 rpm for 1 hr at 230C. The filtrate
was transferred to aglass tube and 200 pl of
80 mM MBB was added. After purging
with nitrogen and mixing, the contents
were incubated for 10 min in the dark at
room temperature. The solution was then
extracted twice with 4 mL dichloro-
methane. After centrifugation at 2500 rpm
for 2 min, the aqueous phase was trans-
ferred into a polypropylene tube, and 17
pL of6M HC1 was added to adjust the pH
to 6-7 before HPLC analysis. The ratios of
the DMSA peak areas to the DMPS peak
area were plotted against the corresponding
DMSA standard concentration. The detec-
tion limit of the assay was 0.25 pM and
within-run variation and the day-to-day
variation was approximately 3-5%.
The method for determining total
DMSA in the plasma samples was similar
to the one used in preparing the DMSA
standards except that 200 pL of the sub-
ject's plasma was used in place ofthe 50 IiL
of DMSA standard and 150 pL of blank
plasma.
Pharmacokinetic analyses. The area
under the curve (AUC) was calculated by
the trapezoidal method for the interval
between 5 hr (i.e., 1 hr after the first dose
ofcholestyramine was given) and 15 hr for
the cholestyramine study and 0-15 hr for
the neomycin study. A priori, absence of
the anticipated postprandial peaks and/or a
decrease in AUC when cholestyramine (or
neomycin) was administered was taken as
support for the hypothesis that DMSA
undergoes enterohepatic circulation.
Results
Study 1: Pharmacokinetics in
Children
The subjects in the two dose groups were
comparable in terms of mean BPb, mean
age, race, and gender (Table 1). The mean
BPbs of the 350 and 700 mg/mi2 groups
were 38 and 39 pg/dL, respectively, and
their mean ages were 3.3 and 4.1 years.
The study population consisted primarily
of ethnic minorities; this is typical of the
pattern of lead poisoning in the United
States. Overall, 5.7 ± 2.6 (SD) and 3.8 +
2.5% of the administered dose of DMSA
was recovered in the urine (as DMSA or
altered DMSA) in the 350 and 700 mg/m2
groups, respectively.
Urinary excretion oflead and unaltered
and altered DMSA were plotted against
time for each child, and a consistent pattern
was observed. Figure 1 illustrates data from
two typical children. Unaltered DMSA
excretion peaked around 4 hr and then fell
and remained at baseline. Altered DMSA
excretion peaked slightly later, returned
almost to the baseline, and then subsequent-
ly rose slightly after each meal. Urinary lead
elimination also rose after meals.
We used urine drug measurements to
obtain crude estimates ofthe early DMSA
half-life ofelimination. The early half-lives
ranged from 1.7 to 3.8 hr, with an overall
mean of 2.6 hr. In the two groups that
received 350 mg/m2 and 700 mg/mi2, the
mean half-lives of2.8 ± 1 hr and 2.5 ± 0.6
hr, respectively, were not significantly dif-
ferent.
There was a significant positive correla-
tion between the initial BPb and DMSA
half-life (r = 0.668, p = 0.049). In other
words, high BPbs were associated with
longer half-lives of elimination of DMSA.
This finding supports the hypothesis that
Table 1. Characteristics of the pediatric study
population
DMSA dose
350mg/m2 700mg/m2
N 5 5
Mean BPb (pg/dL) 38.1 ± 9.7 39.3± 8.4
BPb range (pg/dL) 21.8-46.6 33.1-53.3
Mean age (years) 3.3± 0.9 4.1 ± 3.3
Race/ethnicity
African-American 2 2
Caucasian 1 1
Hispanic 1 2
Indian 1 0
Gender
Male 1 3
Female 4 2
% ofdose 5.7 ± 2.6 3.8± 2.5
recovered in urine
Mean drug half-life (hr) 2.8± 1.0 2.5± 0.6
Abbreviations: DMSA, meso-2,3-dimercaptosuc-
cinic acid; BPb, blood lead.
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Figure 1. Urinary excretion of lead and unaltered and altered meso-2,3-dimercaptosuccinic acid (DMSA) in typical subjects who received either (A) 350mg/m2 or
(B) 700 mg/m2. Unaltered DMSA peaked around 4 hr and then fell to the baseline and did not reappear. Both altered DMSA and lead peaked slightly after 4 hr,
returned almost to the baseline, and then subsequently peaked after meals. DMSA was given at 0600 hr. lunch 6 hr later, dinner at 12 hr later, and breakfastthe
next day at26 hr.
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elevated BPb is associated with slower
DMSA elimination.
On average, ofthe DMSA recovered in
urine, 15.8 ± 14.7% was excreted unal-
tered, with an extremely wide range of
1.3-46.9%. The percentage excreted as
unaltered DMSA was not influenced by
gender (15.0% for boys, 16.3% for girls) or
dose (16.5% and 15.0% for the 350 and
700 mg/m2 groups, respectively).
Furthermore, regression analyses revealed
no associations between the percentage of
unaltered DMSA and either age (r= - 0.08,
p = 0.84) or BPb (r = 0.32, p = 0.37).
There was a hint ofa relationship between
the percentage of unaltered DMSA and
ethnicity: two Caucasians and one Indian
child eliminated only 1-2% unaltered
DMSA, while four African-Americans
eliminated 10-20%, and three Hispanics
eliminated 10, 33, and 44% unaltered
DMSA, respectively. However, ethnicity
was not seen to have any influence in the
subsequent studies with adults videoeinfra).
Study 2: Influence of
Cholestyramine
Total DMSA in plasma was measured at
intervals from 0 to 15 hr after the adminis-
tration ofa single dose of10 mg/kg (rough-
ly equivalent to 350 mg/m2) in six normal
adult subjects with a mean age of29 ± 10
years and a mean BPb of4.4 ± 1.8 pg/dL.
Three were male and three were female. By
design, two were African-American, two
Hispanic, and two Caucasian. Note that
the plasma DMSA assay measures total
DMSA and cannot distinguish between the
altered and unaltered forms (see Methods).
In all six subjects, when DMSA was
administered alone, postprandial peaks in
plasma DMSA were obvious, particularly
after dinner, 10 hr after DMSA adminis-
tration; data from two typical subjects are
illustrated in Figure 2. Cholestyramine
administration at 4, 8, and 12 hr abolished
all evidence ofDMSA reentry (Fig. 2). On
average, cholestyramine significantly
decreased the DMSA versus time
AUC(5-15 hr) by 20% (t = 13.643, p <
0.001; paired t-test). Cholestyramine did
not significantly affect Cmax (54 + 10 pM
versus 55 ± 10 1iM), tmax (2.5 ± 0.4 hr ver-
sus 2.4 ± 0.6 hr) or the initial DMSA half-
life (0-5 hr) (4.1 ± 1.4 hr versus 3.3 ± 1.4
hr). Overall, these findings were taken as
support for the hypothesis that DMSA
undergoes enterohepatic circulation and
that this recycling ofdrug can be interrupt-
ed bycholestyramine.
On average, 18.3 ± 4.9% of the
administered dose was recovered in urine
in 15 hr when DMSA was administered
alone; the range was 11.0-26.3%. Of the
drug eliminated in the urine, the percent-
age eliminated in the unaltered form varied
from 11 to 25% across all subjects.
Study 3: Influence ofNeomycin
The six subjects had a mean age of24 ± 5
years and a mean BPb of2.9 ± 1.1 jig/dL.
When DMSAwas administered alone, post-
prandial peaks in plasma DMSAwere again
obvious (Fig. 3). Neomycin administration
before and after DMSA abolished all evi-
dence of DMSA reentry (Fig. 3). On aver-
age, neomycin significantly decreased Cm.
by 33% (43 ± 14 PM versus 29 ± 13jM,p
< 0.001, paired t-test) and reduced the
DMSAversus time AUC (0-15hr) by 32%
(p < 0.001). Neomycin had no significant
effect on either tmax (2.4 ± 0.5 hr versus 2.5
± 0.5 hr) or the initial DMSA half-life (0-5
hr) (3.4 ± 1.0 hrversus 3.1 ± 1.1 hr).
On average, 10.1 ± 3.5% of the
administered dose ofDMSA was recovered
in the urine in 15 hr when DMSA was
administered alone; the range was
6.9-15.7%. Ofthe drug eliminated in the
urine, the percentage eliminated in the
unaltered form varied from 18 to 35%
across all subjects.
Discussion
The cyclical pattern ofexcretion ofaltered
DMSA in urine observed in children in
study 1 (Fig. 1) is typical for drugs excret-
ed in bile and undergoing enterohepatic
circulation (18). These data, together with
our documentation ofpostprandial reentry
peaks ofDMSA in plasma (Figs. 2 and 3),
lead us to conclude that one or more
metabolites of DMSA undergoes entero-
hepatic circulation. Because compounds
excreted in human bile are typically highly
polar and have molecular weights >400
daltons (18), we speculate that glu-
curonides of DMSA and/or its mixed
disulfides may be secreted into bile.
Although neomycin can interfere with
several small intestine functions, its admin-
istration has been used to demonstrate a
role ofmicroflora in the enterohepatic cir-
culation ofother drugs (23). In the current
study, neomycin decreased AUC and abol-
ished the postprandial peaks of DMSA in
every subject. The decrease in AUC by
neomycin was likely due to both impair-
ment of absorption of the initial DMSA
dose (as indicated by reduced Cmax) and
interruption of enterohepatic circulation
(indicated by abolition of postprandial
peaks of DMSA); an unlikely but possible
explanation is that neomycin bound
DMSA and prevented its absorption. We
conclude, however, that gut microflora
hydrolyze poorly absorbable polar conju-
gates of DMSA, generating more readily
absorbed unconjugated form(s), and are
necessary for the enterohepatic circulation
ofDMSA. The finding that microflora are
required for enterohepatic circulation
implies that concomitant use oforal antibi-
otics may slightly reduce the efficacy of
DMSA. For similar reasons, antibiotic use
reportedly impairs the efficacy oforal con-
traceptives (24,25).
Urinary lead elimination paralleled the
elimination of altered DMSA and not the
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Figure 2. Semilog plots of plasma total meso-2,3-dimercaptosuccinic acid (DMSA) concentration versus time in two typical normal adults (panels A and B) fol-
lowing the administration of a single dose of 10 mg/kg DMSA attime zero. When DMSA was given alone, the plasma DMSA concentration peaked at 2.5 hr and
then fell gradually; postprandial peaks were evident. When DMSAwas given with cholestyramine (CME),the plasma DMSA concentration again peaked at2.5 hr
butfell graduallywithout any evidence of postprandial reentry.
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Figure 3. Semilog plots of plasma total meso-2,3-dimercaptosuccinic acid (DMSA) concentration versus time in two typical normal adults (panels A and B) fol-
lowing the administration of a single dose of 10 mg/kg DMSA attime zero. When DMSA was given alone, the plasma DMSA concentration peaked and then fell
gradually; postprandial peaks were evident. When DMSA was given with neomycin, the plasma DMSA concentration peaked but fell gradually without any evi-
dence of postprandial reentry.
parent DMSA molecule (Fig. 1). It there-
fore appears that a metabolite ofDMSA is
an active lead chelator, if not the active
chelator. Indeed, if we assume that each
urine sample found to have undetectable
amounts of unaltered DMSA had a con-
centration of 0.01 jiM DMSA (i.e., the
detection limit of the assay), we calculate
the average molar ratio of lead:DMSA for
the subjects shown in Figure 1 to be 77.
Thus, the parent DMSA molecule cannot
be responsible for more than a minuscule
portion of the observed postprandial lead
excretion. However, lead is excreted in bile
under basal conditions (26), and we can-
not rule out the possibility that comparable
postprandial lead excretion might have
occurred following a placebo. Thus, the
possibility remains that the postprandial
peaks in the urinary lead observed in study
1 may not be causally related to the excre-
tion ofaltered DMSA.
In 1989, Aposhian and co-workers (12)
first speculated that DMSA may be a pro-
drug after observing that DMSA was rapidly
and extensively eliminated in the altered
form. They subsequently reported that the
major metabolite of DMSA is the 1:2
DMSA:cysteine mixed disulfide (10). They
have since synthesized the 1:2 DMSA:cys-
teine metabolite and administered it to lead-
poisoned rats to examine its efficacy (27).
The 1:2 metabolite increased urinary lead
excretion as compared to saline or cysteine-
treated animals; lead excretion was compa-
rable to that observed in DMSA-treated
rats. However, because DMSA and its
mixed disulfides were detected in the urine
ofboth 1:2 metabolite-treated and DMSA-
treated animals, the authors could not con-
clude that the 1:2 metabolite is the sole
active compound. Another recent study,
however, has clearly demonstrated that the
1:2 mixed disulfide and not DMSA can pre-
vent the in vitro immunotoxicity ofgallium
arsenide (28). Collectively, these studies
imply that the 1:2 DMSA:cysteine metabo-
lite plays a major role in ameliorating heavy-
metal toxicity.
An initial hypothesis of this work was
that the metabolism and/or elimination of
DMSA may be saturable. This hypothesis,
based on an unpublished study in dogs,
was tested by estimating the mean half-life
ofelimination ofDMSA in the children in
the two dose groups. We conclude that
there are no immediately saturable process-
es across the dose range of 350-700
2 mg/iM.
A second hypothesis was that environ-
mental lead exposure, as assessed by BPb,
influences the pharmacokinetics of DMSA
in children. We observed a significant posi-
tive association between BPb and DMSA
half-life, suggesting that lead exposure may
interfere with renal elimination of DMSA.
Although many explanations are possible,
it seems likely that lead may interfere with
renal tubular secretion of DMSA. In rats,
DMSA is eliminated by renal tubular
secretion and is blocked by probenecid
(29). Dart et al. (16) recently reported that
renal DMSA clearance was greater in five
healthy, white male adults than in three
adults and three children with lead poison-
ing, although those findings must be inter-
preted with caution because their controls
differed from the lead-poisoned subjects in
both race and gender. Nevertheless, we
speculate that other drugs excreted by the
kidney, including other chelating agents,
may also be eliminated more slowly in
children with elevated BPbs. Collectively,
these findings reveal a need for more care-
ful assessment of renal tubular secretion
and drug elimination in children with
moderately elevated BPb. 14
In a phase 1 study involving [ C]
DMSA administration to normal male
adult volunteers, 80% of the recovered
radioactivity was found in the feces, 1% in
expired air, and 19% in the urine (9).
HPLC studies in adults also estimated uri-
nary drug recovery at 20% (12). We recov-
ered only about 5% of the administered
dose in urine in the children in study 1, an
unexplained observation that requires fur-
ther study; across the two subsequent stud-
ies in adults, we recovered an average of
14.2% ofthe administered dose of DMSA
in urine in 15 hr. In the 14C study, it was
assumed that fecal radioactivity represented
unabsorbed drug (9). Our findings imply
that fecal drug elimination is partially
derived from bile. Also, while the initial
tl/2e of [14C]DMSA was 2.1 hr, compara-
ble to those observed in our studies, a ter-
minal tl/2e of 2.1 days was also reported.
We suspect that the long second phase of
elimination may reflect storage of drug
metabolites in the gallbladder.
The observation that DMSA and/or a
metabolite undergoes enterohepatic circu-
lation also implies that the drug may also
induce biliary excretion of heavy metals.
All previous studies concerning the efficacy
of DMSA in patients with lead poisoning
have ignored this possibility; only urinary
lead was followed (2-5). For example, in a
dose-ranging study of DMSA in children,
the decline in BPb in response to a 5-day
course oforal DMSA was found to be sig-
nificantly greater than that in response to
intravenous CaNa2EDTA. Yet, urinary
lead output was significantly higher in
patients treated with CaNa2EDTA than in
those who received oral DMSA (2). This
apparent dilemma might have been due to
biliary lead excretion in those who received
oral DMSA.
Reichl et al. (30) studied the effect of
DMSA and other chelators on the excre-
tion of arsenic in bile in guinea pigs. A
dose-dependent rise in biliary arsenic was
observed, along with a rise in the bile/blood
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ratio ofarsenic concentrations. In contrast,
DMSA was not detected in bile after intra-
venous DMSA administration in the rat
(31). It is possible that biliary DMSAexcre-
tion may only occur after oral drug admin-
istration; alternatively, the known species
differences in drug biliary excretion may be
responsible (18).
Finally, we note that enterohepatic
recycling has both pharmacokinetic and
pharmacodynamic implications. In the
event of an accidental DMSA overdose,
cholestyramine may prove to be therapeu-
tically useful. Renowden et al. (32 success-
fully treated a case of warfarin overdose
with cholestyramine. The latter is a far
more palatable antidote than traditional
activated charcoal.
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"Mechanisms and Prevention of Environmentally Caused Cancers", a symposium presented by The
Lovelace Institutes, will be held October 21-25, 1995, in Santa Fe, New Mexico. The purpose of this symposium
is to promote collaboration between scientists interested in the basic mechanisms of environmentally-caused
cancer and investigators focusing on preventing cancer development with chemo-intervention strategies. Dr.
Bruce Ames (University of California) will be the keynote speaker. Other speakers include Dr. Eric Stanbridge
(UC Irvine), Dr. Stephen Friend (Harvard), and Dr. Gary Stoner (Ohio State University).
For further information, please contact:
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